innovation
Oncovita, a spin-off from the Institut Pasteur, achieves new milestone in the treatment of a rare pleural cancer
Oncovita, a spin-off from the Institut Pasteur, has been granted Orphan Drug Designation (ODD) status by the U.S. Food and Drug Administration (FDA) for its MVdeltaC cancer immunotherapy, designed to treat pleural mesothelioma, a rare cancer of the pleura often caused by asbestos.